Spots Global Cancer Trial Database for Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Official Title: Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer
Study ID: NCT00096304
Conditions
Study Description
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when given with docetaxel in treating patients with metastatic prostate cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
Contact Details
Name: Andrew S. Kraft, MD
Affiliation: Medical University of South Carolina
Role: PRINCIPAL_INVESTIGATOR
Name: Gustavo Leone
Affiliation: Medical University of South Carolina, Hollings Cancer Center
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
